METHODS	Forty-six patients with metastatic pancreatic cancer were randomized to receive gemcitabine alone ( n = 25 ; 1,000 mgm ( -2 ) ) or G+C ( n = 21 ; 1,000 mgm ( -2 ) gemcitabine and 25mgm ( -2 ) cisplatin ) .\